Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Pfizer partner BioNTech starts cancer vaccine phase 2 trial

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Jun 24, 2021 9:07am

160 Views

Post# 33440497

RE:RE:RE:RE:RE:RE:RE:RE:RE:Pfizer partner BioNTech starts cancer vaccine phase 2 trial

Thanks Eoga!

Brilliant and Clear as usual. :-)

Eoganacht wrote: Theralase's vaccines are both known as RuVaCare. The anti-cancer vaccine they originally created they just called Ruvacare. When they began work on the the new vaccine for use against Covid-19 they distinguished it from the anti-cancer vaccine by calling it Ruvacare(V)

Rutherrin is the superior photosensitizer Theralase created by combining transferrin (the protein that delivers iron to the cells of the body) with TLD1433. It is Rutherrin which is currently being tested to determine the Maximum Tolerated Dose, and Human Equivalent Dose using non-Good Laboratory Practices and GLP toxicology studies. Theralase will use Rutherrin as the photosensitizer in the upcoming GBM and NSCLC phase 1 trials.

Rutherrin was also used as the photosensitizer when they created the original anti-cancer vaccine - Ruvacare - and the one they will use in creating the anti-pathogen vaccine - Ruvacare(V) for use against Covid-19. What the two vaccines have in common is that the raw material used to create both vaccines came from applyng pdt with Rutherrin on their respective targets. But since one of the targets is cancer cells and the other one is the Covid-19 virus the two vaccines should be very different.

Rumpl3StiltSkin wrote:

Got ya,

I think the key is even though they are both using 1433/Rutherrin or Ruvacare? that they are doing it outside the body with completely different diseases. So how would they then react when introduced back into the body? And both vaccines would then be different than the GLP animal studies they are doing now...Which will probably be fine to set up cancer treatment phase 1s for different indications. The Vaccine part of this ACT is handled a bit differently then it seems?